April 7, 2016 (Shareholders Foundation) - An investigation on behalf of investors of TrovaGene Inc (NASDAQ:TROV) shares over potential securities laws violations by TrovaGene and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of TrovaGene Inc (NASDAQ:TROV) concerning whether a series of statements by TrovaGene Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Shares of TrovaGene Inc (NASDAQ:TROV) declined from $12.83 per share in June 2015 to as low as $2.85 per share on Janaury 19, 2016.
On March 10, 2016, TrovaGene Inc announced its fourth quarter and year end 2015 financial results. TrovaGene Inc reported that its annual Total Revenue increased from $0.28 million in 2014 to $0.31 million in 2015 while its Net Loss increased from $14.33 million in 2014 to $27.47 million in 2015.

On March 28, 2016 TrovaGene Inc announced that the Board of Directors of TrovaGene Inc terminated the employment of CEO Antonius Schuh and CFO Stephen Zaniboni and has filed a complaint against both. The complaint alleges that Dr. Schuh and Mr. Zaniboni failed to present a lucrative corporate opportunity to Trovagene and instead took that prospect for their own personal benefit.